Department of Orthopaedics and Traumatology, Prince of Wales Hospital
Hong Kong
NCT Number: NCT03533010
There is an association between adolescent idiopathic scoliosis (AIS) and low bone mass which has been reported to be a significant prognostic factor for curve progression. Given that dietary calcium (Ca) intake and serum Vit-D levels were also low in AIS, we therefore propose a randomized double-blinded placebo-controlled trial to evaluate if daily [500mg Ca + 800 IU Vit-D] can improve bone health and prevent curve progression in AIS. Immature AIS girls with Cobb angle 10-20 degrees will be randomized either to the Treatment or Placebo group with 3-year of treatment. The main outcome measures for evaluation for those who have completed the 3-year treatment and have reached skeletal maturity at the end of 3-year treatment include: (1) percentage of patients with increase in Cobb angle≥6 degrees and (2) percentage of patients who require bracing. Bone measurements using advanced image acquisition technology(HR-pQCT) to assess bone health will also be evaluated.
Looking for future studies?
Notify Me10 year–14 year
Female
Interventional
Not applicable
Hong Kong
This study investigates if calcium (Ca) plus Vitamin D (Vit-D) supplementation can prevent curve progression and improve bone health in early Adolescent Idiopathic Scoliosis (AIS) during pubertal growth.
AIS is a prevalent three-dimensional spinal deformity mainly affecting girls at puberty. It can lead to serious complications including spine degeneration, cardiopulmonary compromise, grossly deformed torso and psychosocial disorders. Current treatments are far from being satisfactory, with bracing being lengthy and physically demanding and surgery being a major invasive procedure.
There is an association between AIS and low bone mass which has been reported to be a significant prognostic factor for curve progression. Given that dietary calcium intake and serum Vit-D levels were also low in AIS, we therefore propose a randomized double-blinded placebo-controlled trial to evaluate if daily [500mg Ca + 800 IU Vit-D] can improve bone health and prevent curve progression. Immature AIS girls with Cobb angle 10-20 degrees will be randomized either to the Treatment or Placebo group with 3-year of treatment. The main outcome measures for evaluation for those who have completed the 3-year treatment and have reached skeletal maturity at the end of 3-year treatment include: (1) percentage of patients with increase in Cobb angle≥6 degrees and (2) percentage of patients who require bracing. Bone measurements using advanced image acquisition technology (HR-pQCT) to assess bone health will also be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
subjects receive a daily dose of 500mg elemental calcium
Other names: Calcium 500mg
subjects receive a daily dose of 800IU VitD3
Other names: Vitamin D3 800IU
subjects receive placebo tablet
Time frame: 3 years
Percentage of patients with increase in Cobb angle ≥ 6 degrees
Time frame: 3 years
Percentage of patients who require bracing
Time frame: 3 years
Improvement in areal bone mineral density measured with Dual-energy X-ray absorptiometry
Time frame: 3 years
Improvement in bone quality measured with High-resolution peripheral quantitative computed tomography
Chinese University of Hong Kong
Other
Preventing Curve Progression and the Need for Bracing in Early Diagnosed Adolescent Idiopathic Scoliosis Using Calcium Plus Vitamin D Supplementation - A Randomized Double-blinded Placebo-controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06828068
Bone Diseases, Musculoskeletal Disease
Hong Kong
View Trial DetailsNCT02904421
Bone, Bone Diseases
Hong Kong, China
View Trial DetailsNCT01465295
Bone Diseases, Musculoskeletal Diseases
Cincinnati, Ohio, United States
View Trial DetailsNCT00273598
Bone Diseases, Musculoskeletal Diseases
Toronto, Ontario, Canada
View Trial Details